Evidence map›Paper›PMID 37034289›Full record

ArticleJACC. Basic to translational science2023

Apolipoprotein M Attenuates Anthracycline Cardiotoxicity and Lysosomal Injury.

Zhen Guo, Carla Valenzuela Ripoll, Antonino Picataggi, David R Rawnsley, Mualla Ozcan, Julio A Chirinos, Ezhilarasi Chendamarai, Amanda Girardi, Terrence Riehl, Hosannah Evie and 24 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in JACC. Basic to translational science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07174687 (Efficacy of Dapagliflozin in the Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration), which is not on this map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07174687 phase2recruitingnot on this mapstarted 2025, after this paper: background citation

Efficacy of Dapagliflozin in the Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration

TypeinterventionalSponsorWashington University School of MedicineRan2025 to 2028Enrolled70ConditionsRetinal Degeneration, Retinal Diseases, Eye Diseases, Geographic AtrophyArmsDapagliflozin, Matching Placebo
3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 34 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Clinical Insights from Proteomics in Heart Failure.Current heart failure reports · 2025
    Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors at 9 institutions in 2 countries.

Zhen GuoWashington University School of Medicine, St Louis, Missouri, USA.
Carla Valenzuela RipollWashington University School of Medicine, St Louis, Missouri, USA.
Antonino PicataggiWashington University School of Medicine, St Louis, Missouri, USA.
David R RawnsleyWashington University School of Medicine, St Louis, Missouri, USA.
Mualla OzcanWashington University School of Medicine, St Louis, Missouri, USA.
Julio A ChirinosPerelman School of Medicine, University of Pennsylvania School of Medicine/Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Ezhilarasi ChendamaraiWashington University School of Medicine, St Louis, Missouri, USA.
Amanda GirardiWashington University School of Medicine, St Louis, Missouri, USA.
Terrence RiehlWashington University School of Medicine, St Louis, Missouri, USA.
Hosannah EvieWashington University School of Medicine, St Louis, Missouri, USA.
Ahmed DiabWashington University School of Medicine, St Louis, Missouri, USA.
Attila KovacsWashington University School of Medicine, St Louis, Missouri, USA.
Krzysztof HyrcHope Center, Washington University School of Medicine, St Louis, Missouri, USA.
Xiucui MaWashington University School of Medicine, St Louis, Missouri, USA.
Aarti AsnaniBeth Israel Deaconess, Harvard Medical School, Boston, Massachusetts, USA.
Swapnil V ShewalePerelman School of Medicine, University of Pennsylvania School of Medicine/Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Marielle Scherrer-CrosbiePerelman School of Medicine, University of Pennsylvania School of Medicine/Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Lauren Ashley CowartVirginia Commonwealth University, Richmond, Virginia, USA.
John S ParksWake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Lei ZhaoBristol Myers Squibb, Princeton, New Jersey, USA.
David GordonBristol Myers Squibb, Princeton, New Jersey, USA.
Francisco Ramirez-ValleBristol Myers Squibb, Princeton, New Jersey, USA.
Kenneth B MarguliesPerelman School of Medicine, University of Pennsylvania School of Medicine/Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Thomas P CappolaPerelman School of Medicine, University of Pennsylvania School of Medicine/Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Ankit A DesaiIndiana University, Indianapolis, Indiana, USA.
Lauren N PedersenWashington University School of Medicine, St Louis, Missouri, USA.
Carmen BergomWashington University School of Medicine, St Louis, Missouri, USA.
Nathan O StitzielWashington University School of Medicine, St Louis, Missouri, USA.
Michael P RettigWashington University School of Medicine, St Louis, Missouri, USA.
John F DiPersioWashington University School of Medicine, St Louis, Missouri, USA.
Stefan HajnyDepartment of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Christina ChristoffersenDepartment of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Abhinav DiwanWashington University School of Medicine, St Louis, Missouri, USA.
Ali JavaheriWashington University School of Medicine, St Louis, Missouri, USA.
Washington University in St. Louis · USHospital of the University of Pennsylvania · USBristol-Myers Squibb (United States) · USUniversity of Copenhagen · DKBeth Israel Deaconess Medical Center · USHope Center for Neurological Disorders · USIndiana University – Purdue University Indianapolis · USVirginia Commonwealth University · USWake Forest University · US

Funding

Washington University Nutrition Obesity Research CenterP30DK056341 · NIDDK · WASHINGTON UNIVERSITY · PI Dominic N Reeds · 1999 to 2026
$30.2M
WU P&FP30DK020579 · NIDDK · WASHINGTON UNIVERSITY · PI Clay F. Semenkovich · 2013 to 2026
$27.1M
Optimizing Hematopoietic Stem Cell Transplantation For The Treatment Of Hematological MalignanciesR35CA210084 · NCI · WASHINGTON UNIVERSITY · PI John F. Dipersio · 2017 to 2026
$7.8M
MTSS1 in Myocardial DiseaseR01HL141232 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI THOMAS P. CAPPOLA, Scott Michael Damrauer · 2019 to 2026
$4.7M
The Role of Hepatocyte ABCA1 in Lipid Mobilization and TransportR01HL119962 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI PARKS, JOHN S · 2013 to 2022
$3.9M
Apolipoprotein M: a novel regulator of myocardial AutophagyR01HL155344 · NHLBI · WASHINGTON UNIVERSITY · PI JAVAHERI, ALI · 2021 to 2025
$3.1M
Pathogenic Role of IL-18 in Sickle Cell Cardiomyopathy and Inducible Ventricular TachycardiaR01HL136603 · NHLBI · UNIVERSITY OF ARIZONA · PI DESAI, ANKIT A · 2017 to 2021
$2.4M
Genetic Modifiers of Radiation Therapy-Induced CardiotoxicityR01HL147884 · NHLBI · WASHINGTON UNIVERSITY · PI BERGOM, CARMEN · 2019 to 2023
$2.3M
BM NICHE DISRUPTION AND IMMUNOTHERAPY IN HEMATOLOGICAL MALIGNANCIESR50CA211466 · NCI · WASHINGTON UNIVERSITY · PI Michael Rettig · 2016 to 2026
$2.3M
HIGH-RESOLUTON ULTRASOUND SYSTEM FOR PHENOTYPIC EVALUATION OF THE CARDIOVASCULAR SYSTEM IN MICES10OD028597 · OD · WASHINGTON UNIVERSITY · PI KOVACS, ATTILA · 2020 to 2020
$378k
NCI NIH HHS R35 CA210084NCI NIH HHS R50 CA211466NHLBI NIH HHS R01 HL119962NHLBI NIH HHS R01 HL136603NHLBI NIH HHS R01 HL141232NHLBI NIH HHS R01 HL147884NHLBI NIH HHS R01 HL155344NIDDK NIH HHS P30 DK020579NIDDK NIH HHS P30 DK056341NIH HHS S10 OD028597
6 · The paper itself

Abstract

Apolipoprotein M (ApoM) binds sphingosine-1-phosphate (S1P) and is inversely associated with mortality in human heart failure (HF). Here, we show that anthracyclines such as doxorubicin (Dox) reduce circulating ApoM in mice and humans, that ApoM is inversely associated with mortality in patients with anthracycline-induced heart failure, and ApoM heterozygosity in mice increases Dox-induced mortality. In the setting of Dox stress, our studies suggest ApoM can help sustain myocardial autophagic flux in a post-transcriptional manner, attenuate Dox cardiotoxicity, and prevent lysosomal injury.

Indexed as

anthracyclineapolipoprotein MautophagycardiomyopathyTFEB

Identifiers

PMID37034289
PMCPMC10077122
OpenAlexW4313492025

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.